Alkem Labs Announces 52nd AGM on Aug 27, Recommends Final Dividend of ₹10
Alkem Laboratories will hold its 52nd AGM on August 27, 2026, via VC/OAVM. The Board recommended a final dividend of ₹10 per equity share for FY26, payable from September 1, 2026, subject to shareholder approval. TDS will be applicable on dividend payments made after April 1, 2026.
The dividend recommendation and AGM announcement are standard corporate events. The dividend amount is moderate and its impact is likely to be limited to shareholders receiving it.
The announcement includes a positive development of a recommended final dividend, which is generally viewed favorably by investors.
Alkem Laboratories Limited has announced that its 52nd Annual General Meeting (AGM) will be held on Thursday, August 27, 2026, at 11:00 a.m. IST through video conferencing (VC) or other audio-visual means (OAVM). The company will disseminate the Annual Report for the financial year 2025-26 and the Notice of AGM electronically to members whose email IDs are registered.
The Board of Directors, in a meeting held on Thursday, May 28, 2026, recommended a final dividend of ₹10 per equity share of ₹2 each for the financial year ended March 31, 2026. This dividend is subject to the approval of the members at the ensuing AGM. If approved, the final dividend will be paid on or from Tuesday, September 1, 2026.
Members are reminded that dividends paid or distributed on or after April 1, 2026, are taxable in the hands of the members, and the company will be required to deduct tax at source (TDS) at the time of payment. Members are requested to submit the necessary documents to determine the appropriate TDS rate as per the Income-Tax Act, 2025. Detailed tax rates and required documents will be provided in the Notice of AGM.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.